Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. SPY
5. DVN
6. CRGY
7. ZETA
8. ARGX
9. RMR
10. TSM

Go back to Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results

Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy

March 16, 2017 7:28 AM EDT

Maxim Group upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $10.00.

Analyst Jason McCarthy highlighted:

Inovio reported YE16 with $35M in revenue (grants, collaborations) and $112M in operating expenses for a net loss of $74M. The company ended the year with $105M in cash. We expect Inovio will continue to receive grant and collaborative revenue in 2017 which will partially offset operating expenses.... More